Sector News

Fierce JPM Week: Bayer’s new R&D chief wants to push past Aspirin legacy with innovation

January 23, 2022
Life sciences

Christian Rommel, Ph.D., wants to push past Bayer’s legacy—which includes medicine cabinet staple Aspirin—and “really reinvent R&D” at the 150-year old pharmaceutical giant.

“We all agree we don’t want to give the presence to the past, right? So we want to look ahead and shape and invest in innovation,” Rommel, global head of R&D at the pharma, said in a recorded interview as part of Fierce JPM Week, held virtually Jan. 18 to 20.

Rommel, the former Roche oncology leader who joined Bayer early in 2021, has built out a team to help execute on his vision for reshaping Bayer’s pipeline and has played a hand in “arms-length” acquisitions of biotechs that aim to deliver on new technologies for the storied company. One such management move was scouting Christoph Koenen as global head of clinical development and operations from Otsuka Pharmaceutical, where he was chief medical officer, in November.

Speaking ahead of JPM, Rommel said he was excited to see whether he and his colleagues could identify more opportunities to build out Bayer’s pipeline after the $1.5 billion purchase of Vividion last August.

He cautioned that a deal isn’t guaranteed, though, as Bayer’s string of acquisitions over the past few years—radiotherapeutics biotech Noria, gene therapy player AskBio and cell therapy startup BlueRock—will take center stage in the pharma’s pipeline evolution.

“For now, we also have to be reflective and make our investments work, and extract the most value and maintain, especially, these arm lengths,” Rommel said. “That keeps us busy for some time. And we don’t have a blueprint for this, so we want to really learn from the experience before we would add more of those.”

Bayer hopes some of the recent acquisitions will bear fruit in the form of clinical data this year with gene and cell therapy updates from AskBio and BlueRock expected. This includes early-stage tests in Parkinson’s and other rare diseases.

Those results “will, of course, be very pivotal to us to show that the investment in such innovative therapeutic approaches give us a perspective in our innovation strategy,” Rommel said.

For Rommel and his team to make a leap into reinventing a century-old giant, they’ll need those bolt-on acquisitions and other new ways of thinking and developing treatments.

“This is the first time in the history of mankind I think we can really say we are at the doorsteps to unmask, to discover the underlying biology of human diseases in such a comprehensive, precise way,” he said, noting access to genomic profiling, human genetics, data at scale, AI and more.

by Kyle LaHucik

Source: fiercebiotech.com

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).